» Articles » PMID: 36498837

Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Dec 11
PMID 36498837
Authors
Affiliations
Soon will be listed here.
Abstract

Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an external source is especially attractive due to the opportunity to control the activity of an antitumor drug in space and time and avoid damage to normal tissues. In this review, we discuss recent advances in photoabsorber-mediated photocontrollable activation of Pt(IV) prodrugs. Two main approaches developed are the focus of the review. The first one is the photocatalytic strategy based on the flavin derivatives that are not covalently bound to the Pt(IV) substrate. The second one is the conjugation of photoactive molecules with the Pt(II) drug via axial position, yielding dual-action Pt(IV) molecules capable of the controllable release of Pt(II) cytotoxic agents. Thus, Pt(IV) prodrugs with a light-controlled mode of activation are non-toxic in the absence of light, but show high antiproliferative activity when irradiated. The susceptibility of Pt(IV) prodrugs to photoreduction, photoactivation mechanisms, and biological activity is considered in this review.

Citing Articles

Advancements in Biomaterials for Bioengineering and Biotechnology.

Tsouknidas A Int J Mol Sci. 2024; 25(14).

PMID: 39063082 PMC: 11276613. DOI: 10.3390/ijms25147840.


Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties.

Xu L, Kong X, Li X, Zhang B, Deng Y, Wang J Molecules. 2024; 29(4).

PMID: 38398498 PMC: 10892972. DOI: 10.3390/molecules29040746.


Oxidation of the Platinum(II) Anticancer Agent [Pt{(-BrCF)NCHCHNEt}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide.

Ojha R, Junk P, Bond A, Deacon G Molecules. 2023; 28(17).

PMID: 37687231 PMC: 10490441. DOI: 10.3390/molecules28176402.

References
1.
Chen C, Zhang J, Aitken J, Hambley T . Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells. J Med Chem. 2013; 56(21):8757-64. DOI: 10.1021/jm401218n. View

2.
Mazzei L, Martinez A, Trevisan L, Rosa-Gastaldo D, Cortajarena A, Mancin F . Toward supramolecular nanozymes for the photocatalytic activation of Pt(IV) anticancer prodrugs. Chem Commun (Camb). 2020; 56(72):10461-10464. DOI: 10.1039/d0cc03450a. View

3.
Bera A, Gautam S, Raza M, Kondaiah P, Chakravarty A . Oxoplatin-B, a cisplatin-based platinum(IV) complex with photoactive BODIPY for mitochondria specific "chemo-PDT" activity. J Inorg Biochem. 2021; 223:111526. DOI: 10.1016/j.jinorgbio.2021.111526. View

4.
Wexselblatt E, Gibson D . What do we know about the reduction of Pt(IV) pro-drugs?. J Inorg Biochem. 2012; 117:220-9. DOI: 10.1016/j.jinorgbio.2012.06.013. View

5.
MASSEY V . The chemical and biological versatility of riboflavin. Biochem Soc Trans. 2000; 28(4):283-96. View